PROtrol SARS-CoV-2 Lineage B.1.617.2; Delta Variant (Isolate: USA/PHC658/2021) (1 mL)
- Volume: 1.0mL
- Units/Pack: 1
- Storage Condition: -65°C or below
- Hazardous Information: Non-Infectious
- Product Type: Inactivated Organism
For Research Use Only. Not for use in Diagnostic Procedures.
SARS-Related Coronavirus 2 Lineage B.1.617.2; Delta Variant (Isolate: USA/PHC658/2021) is an enveloped, positive-sense single-stranded RNA virus from the Coronaviridae family and the Betacoronaviridae genus. Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/PHC658/2021 was isolated in Memphis, Tennessee, USA in May 2021. Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate hCoV-19/USA/PHC658/2021 is assigned lineage B.1.617.2 using Phylogenetic Assignment of Named Global Outbreak LINeages (PANGOLIN) tool. SARS-CoV-2, lineage B.1.617.2 was first detected in India and labelled as a variant of concern (VOC). It was labelled as Delta variant by the World Health Organization (WHO).
SARS-CoV-2 was propagated in VeroE6 cells. The viral culture fluid was clarified via centrifugation to remove cellular debris prior to inactivation.
PROtrol™ (Protein control) is formulated with viral particles that have been modified to render them non-infectious. Each vial contains 1.0 mL of SARS- CoV-2 PROtrol™ frozen in 2% MEM media.
The pre-inactivation titer was determined from an infectious aliquot. Each lot of PROtrol™ is tested using an N-protein ELISA developed internally at ZeptoMetrix. Viral inactivation is verified by the absence of viral growth in tissue culture-based infectivity assay.
PROtrol™ is intended for use in analytical and quality control testing of antigen-based assays. The suitability and performance characteristics should be determined by your laboratory for each intended usage.
These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act or for any other product intended for administration to humans.